{"id":54780,"date":"2023-03-13T20:03:07","date_gmt":"2023-03-13T19:03:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/"},"modified":"2023-03-13T20:03:07","modified_gmt":"2023-03-13T19:03:07","slug":"bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/","title":{"rendered":"Bryn Pharma Announces Appointment of Sandy Loreaux as CEO"},"content":{"rendered":"
\n

RALEIGH, N.C.–(BUSINESS WIRE)–#anaphylaxis<\/a>–Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, announced today that pharmaceutical industry veteran Sandy Loreaux has been appointed CEO, effective immediately. David Dworaczyk, Ph.D., is transitioning from the CEO role and will stay on as a senior advisor and head of R&D, Regulatory, and production efforts as Bryn works toward the completion and filing of the NDA for the company\u2019s lead candidate, investigational epinephrine nasal spray, UTULY\u2122.\n<\/p>\n

<\/a><\/p>\n

\nPivotal trial results<\/a> demonstrate that UTULY has quick uptake, with higher and more sustained epinephrine levels than the current standard of care, the epinephrine autoinjector (EpiPen).\n<\/p>\n

\n\u201cOver the past 5-plus years, we\u2019ve been a development-stage company focusing on UTULY\u2019s NDA submission and approval. David\u2019s efforts have brought us from an idea of building a non-needle, easy to use, easy to carry emergency epinephrine delivery device to being on the cusp of filing our NDA. We appreciate David\u2019s dedication, development expertise, scientific acumen and continued insights as he leads the completion and filing of UTULY\u2019s NDA submission. Now we must evolve into a commercial-stage company. Sandy\u2019s extensive pharmaceutical commercialization and leadership experience will be instrumental to Bryn as we advance UTULY. While Sandy has already made significant contributions to Bryn as a member of our Board of Directors, her day-to-day involvement comes at a critical time to guide us through a successful launch,\u201d said Steven Hartman, Co-Founder and Chairman of the Board of Directors.\n<\/p>\n

\n\u201cSandy and I share both a connection and a commitment to the food allergy community as mothers of children with life-threatening food allergies,\u201d said Bryn Co-Founder Michelle Lobel. \u201cEarly treatment during anaphylaxis can be life-saving, but patients and caregivers often hesitate due to fear of needles. We have been diligently working to bring a quick-acting needle-free epinephrine alternative to market. Sandy\u2019s stellar combination of passion and expertise at the helm of Bryn will help us bring this vision to life.\u201d\n<\/p>\n

\nMs. Loreaux has over 25 years of experience in the pharmaceutical industry. Over the course of her career, she has worked across multiple therapeutic areas, including allergy and the epinephrine autoinjector space. She most recently led Covis Pharma\u2019s U.S. Operations as U.S. President. Sandy joined Covis after serving as Senior Vice President and General Manager, U.S. Critical Care for Mallinckrodt Pharmaceuticals. She has led multiple market access organizations and has served as SVP, Head of Market Access at Mallinckrodt Pharmaceuticals and SVP, Head of Market Access, and Commercial Operations at Bausch Health. Ms. Loreaux spent the first 19 years of her career at Sanofi and its legacy companies in various roles of increasing responsibility across medical affairs, sales, marketing and market access. Ms. Loreaux is a pharmacist by training and has a degree from Temple University School of Pharmacy in Philadelphia. As a mother of twin boys who were diagnosed with life-threatening food allergies as infants, Ms. Loreaux brings a personal passion and commitment to bringing epinephrine delivery alternatives to market.\n<\/p>\n

\nAbout Bryn Pharma<\/b>\n<\/p>\n

\nBryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction. For more information visit www.brynpharma.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nRebecca Novak Tibbitt
\n
Rebecca@RNTCommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

RALEIGH, N.C.–(BUSINESS WIRE)–#anaphylaxis–Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, announced today that pharmaceutical industry veteran Sandy Loreaux has been appointed CEO, effective immediately. David Dworaczyk, Ph.D., is transitioning from the CEO role and will stay on as a senior advisor and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54780","6":"format-standard","7":"category-industry"},"yoast_head":"\nBryn Pharma Announces Appointment of Sandy Loreaux as CEO - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bryn Pharma Announces Appointment of Sandy Loreaux as CEO - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"RALEIGH, N.C.–(BUSINESS WIRE)–#anaphylaxis–Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, announced today that pharmaceutical industry veteran Sandy Loreaux has been appointed CEO, effective immediately. David Dworaczyk, Ph.D., is transitioning from the CEO role and will stay on as a senior advisor and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-13T19:03:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230313005666\/en\/1569207\/21\/Bryn_Corporate_V2_500x250.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Bryn Pharma Announces Appointment of Sandy Loreaux as CEO\",\"datePublished\":\"2023-03-13T19:03:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/\"},\"wordCount\":605,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005666\\\/en\\\/1569207\\\/21\\\/Bryn_Corporate_V2_500x250.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/\",\"name\":\"Bryn Pharma Announces Appointment of Sandy Loreaux as CEO - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005666\\\/en\\\/1569207\\\/21\\\/Bryn_Corporate_V2_500x250.jpg\",\"datePublished\":\"2023-03-13T19:03:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005666\\\/en\\\/1569207\\\/21\\\/Bryn_Corporate_V2_500x250.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005666\\\/en\\\/1569207\\\/21\\\/Bryn_Corporate_V2_500x250.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bryn Pharma Announces Appointment of Sandy Loreaux as CEO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bryn Pharma Announces Appointment of Sandy Loreaux as CEO - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/","og_locale":"en_US","og_type":"article","og_title":"Bryn Pharma Announces Appointment of Sandy Loreaux as CEO - Pharma Trend","og_description":"RALEIGH, N.C.–(BUSINESS WIRE)–#anaphylaxis–Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, announced today that pharmaceutical industry veteran Sandy Loreaux has been appointed CEO, effective immediately. David Dworaczyk, Ph.D., is transitioning from the CEO role and will stay on as a senior advisor and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-13T19:03:07+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230313005666\/en\/1569207\/21\/Bryn_Corporate_V2_500x250.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Bryn Pharma Announces Appointment of Sandy Loreaux as CEO","datePublished":"2023-03-13T19:03:07+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/"},"wordCount":605,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230313005666\/en\/1569207\/21\/Bryn_Corporate_V2_500x250.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/","url":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/","name":"Bryn Pharma Announces Appointment of Sandy Loreaux as CEO - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230313005666\/en\/1569207\/21\/Bryn_Corporate_V2_500x250.jpg","datePublished":"2023-03-13T19:03:07+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230313005666\/en\/1569207\/21\/Bryn_Corporate_V2_500x250.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230313005666\/en\/1569207\/21\/Bryn_Corporate_V2_500x250.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bryn-pharma-announces-appointment-of-sandy-loreaux-as-ceo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Bryn Pharma Announces Appointment of Sandy Loreaux as CEO"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54780"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54780\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}